CD4 and diabetes mellitus: PFK15 treatment has been reported to increase the expression of PD-1 and LAG-3(lymphocyte-activation gene 3) on CD4 T cells and prevent the development of diabetes via inhibiting glycolysis utilization of diabetogenic CD4 T cells and reducing T cell responses to β cell antigen (105, 106).